What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?;Que nous apprennent les grands essais cliniques de prévention cardiovasculaire et rénale chez le malade diabétique de type 2 hypertendu ?

Nephrologie et Therapeutique

Volumn 2, Issue 2, 2006, Pages 51-74

  Dussol, Bertrand ^a   Berland, Yvon ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Cardiovascular risk; Clinical trial; Hypertension; Macroproteinuria; Microalbuminuria; Randomisation; Renal failure; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CHLORPROPAMIDE; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; METFORMIN; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PRAVASTATIN; SIMVASTATIN; SULFANILAMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ARTICLE; BODY BURDEN; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FREQUENCY ANALYSIS; GLYCEMIC CONTROL; HUMAN; HYGIENE; HYPERTENSION; KIDNEY FUNCTION; LEARNING; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; PRESCRIPTION; PROTEINURIA; RENAL PROTECTION; TIME SERIES ANALYSIS; TREATMENT OUTCOME; URINARY EXCRETION; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; KIDNEY DISEASE; PATHOPHYSIOLOGY; REVIEW; STANDARD;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY DISEASES;

EID: 33745506648     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2006.01.004     Document Type: Article

References (126)

1. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025. Diabetes Care 21 (1998) 1414-1431
2. Engelgau M.M., Geiss L.S., Saaddine J.B., Boyle J.P., Benjamin S.M., Gregg E.W., et al. The evolving diabetes burden in the United States. Ann. Intern. Med. 140 (2004) 945-950
3. Charles M.A. Une mise au point sur l'épidémiologie de l'obésité et du diabète de type 2 en France. Diabetes Metab. 26 suppl 3 (2000) 17-20
4. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
5. Wannamethee S.G., and Shaper A.G. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 22 (1999) 1266-1272
6. Charles M.A., Basdevant A., and Eschwege E. Prévalence de l'obésité chez l'adulte en France : la situation en 2000 établie à partir de l'étude OBEPI. Ann. Endocrinol. (Paris) 63 (2002) 154-158
7. Kannel W.B., and McGee D.L. Diabetes and cardiovascular risk factors. The Framingham study. JAMA 241 (1979) 2035-2038
8. Stamler J., Vaccaro O., and Neaton J. Diabetes, other risk factors, and the 12-year cardiovascular mortality for men in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
9. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
10. Malmberg K., Yusuf S., Gerstein H.C., Brown J., Zhao F., Hunt D., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS registry. Circulation 102 (2000) 1014-1019
11. Hu F.B., Stampfer M.J., Solomon C.G., Liu S., Willett W.C., Speizer F.E., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch. Intern. Med. 161 (2001) 1717-1723
12. Kannel W.B., and McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease. The Framingham study. Diabetes Care 2 (1979) 120-126
13. Grimaldi A., and Heurtier A. Épidémiologie des complications cardiovasculaires du diabète. Diabetes Metab. 25 Suppl 3 (1999) 12-20
14. Sowers J.R., Epstein M., and Frohlich E.D. Diabetes, hypertension and cardiovascular disease. Hypertension 37 (2001) 1053-1059
15. Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. J. Hum. Hypertens. 13 (1999) S3-S8
16. Tarnow L., Rossing P., Gall M.A., Nielsen F.S., and Parving H.H. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17 (1994) 1247-1251
17. Deedwania P.C. Hypertension and diabetes. New therapeutic options. Arch. Intern. Med. 160 (2000) 1585
18. Cooper M.E., and Johnston C.I. Optimizing treatment of hypertension in patients with diabetes. JAMA 283 (2000) 3177-3179
19. Jandeleit-Dahm K., and Cooper M.E. Hypertension and diabetes. Curr. Opin. Nephrol. Hypertens. 11 (2000) 221-228
20. Weiner D.E., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 15 (2004) 1307-1315
21. Vlagopoulos P.T., and Sarnak M.J. Traditional and non-traditional cardiovascular risk factors in chronic kidney disease. Med. Clin. North Am. 89 (2005) 587-611
22. Fox C.S., Larson M.G., Keyes M.J., Levy D., Clouse M.E., Culleton B., et al. Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: the Framingham Heart Study. Kidney Int. 66 (2004) 2017-2021
23. Yokoyama H., Okudaira M., Otani T., Sato A., Miura J., Takaike H., et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 58 (2000) 302-311
24. Hasslacher C., Ritz E., Wahl P., and Michael C. Similar risk of nephropathy in patients with type 1 and type 2 diabetes mellitus. Nephrol. Dial. Transplant. 4 (1989) 859-863
25. Ritz E., and Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 341 (1999) 1127-1133
26. Gambara V., Mecca G., Remuzzi G., and Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J. Am. Soc. Nephrol. 3 (1993) 1458-1466
27. Keller C.K., Bergis K.H., Fliser D., and Ritz E. Renal findings in patients with short-term type 2 diabetes. J. Am. Soc. Nephrol. 7 (1996) 2627-2635
28. Remuzzi G., Schieppati A., and Ruggenenti P. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346 (2002) 1145-1151
29. Gall M.A., Hougaard P., Borch-Johnsen K., and Parving H.H. Risk factors for development of incipient and overt nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314 (1997) 738-748
30. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., and Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63 (2003) 225-232
31. USRDS (United States Renal Data System). Excerpts from the USRDS 2003 annual data report. Incidence and prevalence of ESRD. Am. J. Kidney Dis. 42 (2003) S47-S60
32. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310 (1984) 356-360
33. MacLeod J.M., Lutale J., and Marshall S.M. Albumin excretion and vascular deaths in NIDDM. Diabetologia 38 (1995) 610-616
34. Miettinen H., Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non-diabetic and non-insulin-dependent diabetic subjects. Stroke 27 (1996) 2033-2039
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
37. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., and for The STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 290 (2003) 486-494
38. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
39. Virally M.L., Kevorkian J.P., Riveline J.P., Varroud-Vial M., Requeda E., and Charpentier G. Prévention du diabète de type 2. Sang Thrombose Vaisseaux 16 (2004) 193-199
40. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
41. Haffner S.M., Alexander C.M., Cook T.J., Boccuzzi S.J., Musliner T.A., Pedersen T.R., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch. Intern. Med. 159 (1999) 2661-2667
42. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335 (1996) 1001-1009
43. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The CARE investigators. Circulation 8 (1998) 2513-2519
44. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339 (1998) 1349-1357
45. Keech A., Colquhoun D., Best J., Simes R.J., Hunt D., Hague W., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003) 2713-2721
46. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
48. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
49. Sever P.S., Poulter N.R., Dahlöf B., Wedel H., Collins R., Beevers G., et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
50. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular events with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
51. Lièvre M. Diabète de type 2 et risque cardiovasculaire : enseignements des essais thérapeutiques. Rev. Prat. 51 (2001) 1793-1799
52. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
53. Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A.N., Mahmood S., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the Saint-Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP). Study. Diabetes Care 21 (1998) 641-648
54. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction (BIP) study. Circulation 102 (2000) 21-27
55. Arcavi L., Behar S., Caspi A., Reshef N., Boyko V., and Knobler H. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am. Heart J. 147 (2004) 239-245
56. Bloomfield Rubins H., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341 (1999) 410-418
57. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of Veteran Affairs High-density lipoprotein Intervention Trial (VA-HIT). Arch. Intern. Med. 162 (2002) 2597-2604
58. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. JAMA 242 (1979) 2562-2571
59. Curb J.D., Pressel S.L., Cutler J.A., Savage P.J., Applegate W.B., Black H., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276 (1996) 1886-1892
60. Dahlöf B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., and Wester P.O. Morbidity and mortality in the swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 338 (1991) 1281-1285
61. Tuomilehto J., Rastenyte D., Birkenhäger W.H., Thijs L., Antikainen R., Bulpitt C.J., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 340 (1999) 677-684
62. Lièvre M., Gueyffier F., Ekbom T., Fagard R., Cutler J., Schron E., et al. Efficacy of diuretics and β-blockers in diabetic hypertensive patients. Results from a meta-analysis. Diabetes Care 23 suppl 2 (2000) B65-B71
63. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317 (1998) 703-713
64. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Ménard J., et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet 351 (1998) 1755-1762
65. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 25 suppl 1 (2002) S80-S82
66. Working Party of the International Diabetes Federation (European region). Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabetes Med. 20 (2003) 972-987
67. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 289 (2003) 2560-2572
68. Hollenberg N.K. Treatment of the patient with diabetes mellitus and risk of nephropathy. What do we know, and what do we need to learn?. Arch. Intern. Med. 164 (2004) 125-130
69. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 317 (1998) 713-720
70. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared to conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
71. Tatti P., Pahor M., Byington R.P., Di Mauro P., Guarisco R., Strollo G., et al. Outcome results of the fosinopril vs amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 (1998) 597-603
72. Brown M.J., Palmer C.R., Castaigne A., de Leeuw P.W., Mancia G., Rosenthal T., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a goal in hypertension treatment. Lancet 356 (2000) 366-372
73. Mancia G., Brown M.J., Castaigne A., de Leeuw P.W., Palmer C.R., Rosenthal T., et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 41 (2003) 431-436
74. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., and Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338 (1998) 645-652
75. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem study. Lancet 356 (2000) 359-365
76. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
77. Lindholm L.H., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
78. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288 (2002) 2981-2997
79. Rahman M., Pressel S., Davis B.R., Nwachuku C., Wright J.T., Whelton P.K., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic. Arch. Intern. Med. 165 (2005) 936-946
80. Zucchelli P. Calcium channel blockers in diabetic nephropathy-is there a life after the ABCD trial?. Nephrol. Dial. Tansplant. 13 (1998) 1930-1932
81. McMurray J., and Murdoch D. Calcium-antagonist controversy: the long and short of it?. Lancet 349 (1997) 585-586
82. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342 (2000) 145-153
83. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
84. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
85. Daly C.A., Fox K.M., Remme W.J., Bertrand M.E., Ferrari R., Simoons L.M., and on behalf of the EUROPA investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur. Heart J. (2005) (in press)
86. Svensson P., de Faire U., Sleight P., Yusuf S., and Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38 (2001) E28-E32
87. Mancini G.B., and Stewart D.J. Why were the results if the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?. Can. J. Cardiol. 17 suppl A (2001) 15A-17A
88. Antiplatelet Trialist's Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
89. Colwell J.A., and Nesto R.W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26 (2003) 2181-2188
90. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28 (1995) 103-117
91. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., and Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 128 (1998) 982-988
92. Estacio R.O., Jeffers B.W., Gifford N., and Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 suppl 2 (2000) B54-B64
93. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P., Brusegan V., et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351 (2004) 1941-1951
94. Ahmad J., Siddiqui M.A., and Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20 (1997) 1576-1581
95. Zandbergen A.A.M., Baggen M.G.A., Lamberts S.W.J., Bootsma A.H., de Zeeuw D., and Ouwendijk R.J.T. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Ann. Intern. Med. 139 (2003) 90-96
96. Muirhead N., Feagan B.F., Mahon J., Lewanczuk R.Z., Rodger N.W., Botteri F., et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr. Ther. Res. 60 (1999) 650-660
97. Mogensen C.E., Viberti G., Halimi S., Ritz E., Ruilope L., Jermendy G., et al. Effects of low dose perindopril-indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 41 (2003) 1063-1071
98. Esnault V., Ekhlas A., Delcroix C., Moutel M.G., and Nguyen J.M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J. Am. Soc. Nephrol. 16 (2005) 474-481
99. Heeg J.E., De Jong P.E., Van Der Hem G.K., and De Zeeuw D. Efficacy and variability of the antiproteinuric effect of lisinopril. Kidney Int. 36 (1989) 272-279
100. Viberti G., Wheeldon N.M., and for the MicroAlbuminuria Reduction With VALsartan Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106 (2002) 672-678
101. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
102. Agardh C.D., Garcia-Puig J., Charbonnel B., Angelkort B., and Barnett A.H. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens. 10 (1996) 185-192
103. Parving H.H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345 (2001) 870-878
104. Barnett H.A., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J., et al. Angiotensin-receptor blockade vs converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 351 (2004) 1952-1961
105. Feldt-Rasmussen B., Mathiesen E.R., and Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 2 (1986) 1300-1304
106. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
107. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 (2001) 851-860
108. Hannedouche T., Richter S., and Krummel T. Revue critique des essais prospectifs rénaux et cardiovasculaires récents : quelles conséquences pratiques en néphrologie ?. Actualités Néphrologiques 2002 (2002), Flammarion Médecine-Sciences, Paris 179-192
109. Bakris G.L., Weir M.R., Shanifar S., Zhang Z., Douglas J., van Dijk D.J., et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med. 163 (2003) 1555-1565
110. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J. Am. Soc. Nephrol. 16 (2005) 2170-2179
111. Locatelli F., Del Vecchio L., D'Amico M., and Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies?. J. Am. Soc. Nephrol. 13 (2002) S196-S201
112. Vogt L., Navis G., and de Zeeuw D. Renoprotection: a matter of blood pressure reduction or agent-characteristics?. J. Am. Soc. Nephrol. 13 (2002) S202-S207
113. Epstein M. Calcium antagonists and renal disease. Kidney Int. 54 (1998) 1774-1784
114. Rossing K., Jacobsen P., Pietraszek L., and Parving H.H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabees Care 26 (2003) 2268-2274
115. Pijls L.T., de Vries H., van Eijk J.T., and Donker A.J. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur. J. Clin. Nutr. 56 (2002) 1200-1207
116. Dussol B., Iovanna C., Raccah D., Darmon P., Morange S., Vague P., et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. J. Ren. Nutr. 15 (2005) 398-406
117. Hansen H.P., Tauber-Lassen E., Jensen B.R., and Parving H.H. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 62 (2002) 220-228
118. Tuck M., Corry D., and Trujillo A. Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. Am. J. Med. 88 (1990) 210-216
119. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D., et al. for the DASH-Sodium Collaborative Research Group. Effect on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N. Engl. J. Med. 344 (2001) 3-10
120. Facchini F.S., and Saylor K.L. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52 (2003) 1204-1209
121. Orth S.R. Smoking -- a renal risk factor. Nephron 86 (2000) 12-26
122. Klein R., Klein B.E.K., and Moss S.E. incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes 42 (1993) 381-389
123. Chuahirun T., and Wesson D.E. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am. J. Kidney Dis. 39 (2002) 376-382
124. Malarcher A.M., Ford E.S., Nelson D.E., Chrismon J.H., Mowery P., Merritt R.K., et al. Trends in cigarette smoking and physicians' advice to quit smoking among people in the US. Diabetes Care 18 (1995) 694-697
125. Gaede P., Vedel P., Parving H.H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the STENO type 2 randomised study. Lancet 353 (1999) 617-622
126. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003) 383-393